Deuterated (“heavy”) water labeling in CLL patients demonstrates that IGHV unmutated and ZAP-70+ patients have higher blood and tissue CLL death rates on ibrutinib therapy, resulting in lower measurable residual disease levels with long-term ibrutinib treatment. This trial was registered at www.clinicaltrials.gov as #NCT01752426.

中文翻译：

---

伊布替尼治疗 CLL 患者的氘代水标记：白血病细胞动力学与 IGHV、ZAP-70 和 MRD 相关


CLL 患者的氘代（“重”）水标记表明，IGHV 未突变和 ZAP-70+ 患者在伊布替尼治疗期间具有更高的血液和组织 CLL 死亡率，导致长期伊布替尼治疗的可测量残留病灶水平较低。该试验在 www.clinicaltrials.gov 注册为 #NCT01752426。